JP2021533198A5 - - Google Patents
Info
- Publication number
- JP2021533198A5 JP2021533198A5 JP2021529259A JP2021529259A JP2021533198A5 JP 2021533198 A5 JP2021533198 A5 JP 2021533198A5 JP 2021529259 A JP2021529259 A JP 2021529259A JP 2021529259 A JP2021529259 A JP 2021529259A JP 2021533198 A5 JP2021533198 A5 JP 2021533198A5
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- oligonucleotide
- transferrin receptor
- complex according
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024184975A JP7708957B2 (ja) | 2018-08-02 | 2024-10-21 | 筋標的化複合体およびそれらの使用 |
| JP2025112731A JP2025175995A (ja) | 2018-08-02 | 2025-07-03 | 筋標的化複合体およびそれらの使用 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862714010P | 2018-08-02 | 2018-08-02 | |
| US62/714,010 | 2018-08-02 | ||
| US201862779173P | 2018-12-13 | 2018-12-13 | |
| US62/779,173 | 2018-12-13 | ||
| US201962855781P | 2019-05-31 | 2019-05-31 | |
| US62/855,781 | 2019-05-31 | ||
| US201962858925P | 2019-06-07 | 2019-06-07 | |
| US62/858,925 | 2019-06-07 | ||
| US201962859694P | 2019-06-10 | 2019-06-10 | |
| US62/859,694 | 2019-06-10 | ||
| PCT/US2019/044982 WO2020028857A1 (en) | 2018-08-02 | 2019-08-02 | Muscle-targeting complexes and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024184975A Division JP7708957B2 (ja) | 2018-08-02 | 2024-10-21 | 筋標的化複合体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533198A JP2021533198A (ja) | 2021-12-02 |
| JP2021533198A5 true JP2021533198A5 (enExample) | 2022-08-10 |
| JP7576542B2 JP7576542B2 (ja) | 2024-10-31 |
Family
ID=69232332
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529259A Active JP7576542B2 (ja) | 2018-08-02 | 2019-08-02 | 筋標的化複合体およびそれらの使用 |
| JP2024184975A Active JP7708957B2 (ja) | 2018-08-02 | 2024-10-21 | 筋標的化複合体およびそれらの使用 |
| JP2025112731A Pending JP2025175995A (ja) | 2018-08-02 | 2025-07-03 | 筋標的化複合体およびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024184975A Active JP7708957B2 (ja) | 2018-08-02 | 2024-10-21 | 筋標的化複合体およびそれらの使用 |
| JP2025112731A Pending JP2025175995A (ja) | 2018-08-02 | 2025-07-03 | 筋標的化複合体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210261680A1 (enExample) |
| EP (1) | EP3829649A4 (enExample) |
| JP (3) | JP7576542B2 (enExample) |
| KR (1) | KR20210086602A (enExample) |
| CN (1) | CN112930197A (enExample) |
| AU (1) | AU2019315593A1 (enExample) |
| CA (1) | CA3108335A1 (enExample) |
| IL (3) | IL280536B2 (enExample) |
| MX (1) | MX2021001282A (enExample) |
| SG (1) | SG11202100931QA (enExample) |
| WO (1) | WO2020028857A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| AU2018378812B2 (en) * | 2017-12-06 | 2025-05-22 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| KR20210086601A (ko) * | 2018-08-02 | 2021-07-08 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 프리드라이히 운동실조를 치료하기 위한 그의 용도 |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| IL280536B2 (en) * | 2018-08-02 | 2024-12-01 | Dyne Therapeutics Inc | Complexes targeting transferrin receptor and uses thereof |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| AU2021206234A1 (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| SI4126066T1 (sl) | 2020-03-27 | 2026-04-30 | Avidity Biosciences, Inc. | Sestavki in postopki zdravljenja mišične distrofije |
| WO2021226107A1 (en) * | 2020-05-05 | 2021-11-11 | Avidity Biosciences, Inc. | Compositions and methods of treating pompe disease |
| JP2023524812A (ja) * | 2020-05-08 | 2023-06-13 | エムペグ エルエイ リミテッド ライアビリティ カンパニー | リンカー化合物 |
| JP2023535078A (ja) * | 2020-07-23 | 2023-08-15 | ダイン セラピューティクス，インコーポレーテッド | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
| CN116194470B (zh) * | 2020-07-23 | 2025-10-03 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| IL303332A (en) * | 2020-12-04 | 2023-07-01 | Dyne Therapeutics Inc | Antibody-oligonucleotide complexes and their uses |
| CA3202832A1 (en) * | 2020-12-31 | 2022-07-07 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2022197554A1 (en) * | 2021-03-16 | 2022-09-22 | University Of Massachusetts | Photocaged citrulline analogs and methods for site-specific incorporation of citrulline into proteins |
| JP2024525608A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| AU2022309238A1 (en) * | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| JP2024525611A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2023023031A2 (en) * | 2021-08-17 | 2023-02-23 | Blaze Bioscience, Inc. | Transferrin receptor targeting peptide oligonucleotide complexes and methods of use thereof |
| WO2023034409A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| KR20240067118A (ko) * | 2021-09-29 | 2024-05-16 | 아이오니스 파마수티컬즈, 인코포레이티드 | 접합된 올리고뉴클레오타이드 및 이의 용도 |
| JP2025500481A (ja) | 2021-12-22 | 2025-01-09 | サプリーム テクノロジーズ，ベー．フェー． | 筋消耗性障害を治療するための治療用核酸とサポニンとを含む組成物 |
| US20250057971A1 (en) | 2021-12-22 | 2025-02-20 | Sapreme Technologies B.V. | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders |
| WO2023121444A1 (en) | 2021-12-22 | 2023-06-29 | Sapreme Technologies B.V. | Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders |
| TW202345894A (zh) * | 2022-01-07 | 2023-12-01 | 美商密瑞克公司 | 靶向表現於肌肉細胞表面的蛋白質之組織特異性顯像及治療劑 |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| EP4612184A1 (en) * | 2022-11-04 | 2025-09-10 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
| EP4480964A1 (en) * | 2023-06-22 | 2024-12-25 | Vect-Horus | Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat muscular diseases |
| CN121794291A (zh) * | 2023-06-22 | 2026-04-03 | 维克塔-霍洛斯公司 | 转铁蛋白受体结合分子、其偶联物及其用于预防或治疗肌肉疾病的用途 |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040063654A1 (en) * | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
| US20120122801A1 (en) * | 2005-01-05 | 2012-05-17 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
| AU2010306940A1 (en) * | 2009-10-12 | 2012-06-07 | Smith, Larry | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
| CN107080847A (zh) * | 2011-06-24 | 2017-08-22 | 森彻斯有限公司 | 细胞外靶向药物缀合物 |
| CN105142672B (zh) | 2012-10-23 | 2019-04-05 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| ES2886531T3 (es) * | 2013-01-07 | 2021-12-20 | Omniox Inc | Formas poliméricas de proteínas H-NOX |
| GB201507926D0 (en) * | 2015-05-08 | 2015-06-24 | Proqr Therapeutics N V | Improved treatments using oligonucleotides |
| DK3473270T5 (da) | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| IL280536B2 (en) * | 2018-08-02 | 2024-12-01 | Dyne Therapeutics Inc | Complexes targeting transferrin receptor and uses thereof |
-
2019
- 2019-08-02 IL IL280536A patent/IL280536B2/en unknown
- 2019-08-02 IL IL320597A patent/IL320597A/en unknown
- 2019-08-02 US US17/264,998 patent/US20210261680A1/en not_active Abandoned
- 2019-08-02 JP JP2021529259A patent/JP7576542B2/ja active Active
- 2019-08-02 CA CA3108335A patent/CA3108335A1/en active Pending
- 2019-08-02 WO PCT/US2019/044982 patent/WO2020028857A1/en not_active Ceased
- 2019-08-02 IL IL314102A patent/IL314102B2/en unknown
- 2019-08-02 CN CN201980064587.3A patent/CN112930197A/zh active Pending
- 2019-08-02 EP EP19843251.0A patent/EP3829649A4/en active Pending
- 2019-08-02 SG SG11202100931QA patent/SG11202100931QA/en unknown
- 2019-08-02 MX MX2021001282A patent/MX2021001282A/es unknown
- 2019-08-02 AU AU2019315593A patent/AU2019315593A1/en active Pending
- 2019-08-02 KR KR1020217006030A patent/KR20210086602A/ko active Pending
-
2021
- 2021-03-18 US US17/205,139 patent/US20210228730A1/en active Pending
-
2024
- 2024-10-21 JP JP2024184975A patent/JP7708957B2/ja active Active
-
2025
- 2025-07-03 JP JP2025112731A patent/JP2025175995A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533198A5 (enExample) | ||
| JP2021533197A5 (enExample) | ||
| JP2021533199A5 (enExample) | ||
| JP2021533200A5 (enExample) | ||
| JP2025067909A5 (enExample) | ||
| JP2021532832A5 (enExample) | ||
| JP2023535073A5 (enExample) | ||
| JP2021532831A5 (enExample) | ||
| JP2023510351A5 (enExample) | ||
| JP2023535074A5 (enExample) | ||
| JP2023535078A5 (enExample) | ||
| EP2451480B1 (en) | A complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent | |
| JP2023512442A5 (enExample) | ||
| Uherek et al. | DNA-carrier proteins for targeted gene delivery | |
| JP2024501872A5 (enExample) | ||
| Klein et al. | Centyrin ligands for extrahepatic delivery of siRNA | |
| JP2023535444A5 (enExample) | ||
| JP2023512441A5 (enExample) | ||
| JP2023509793A5 (enExample) | ||
| TW202202173A (zh) | 治療肌肉萎縮症之組合物及方法 | |
| CN112930193A (zh) | 肌肉靶向复合物及其在治疗肌肉萎缩中的用途 | |
| CN112955154A (zh) | 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途 | |
| CN112912399A (zh) | 肌肉靶向复合物及其用于治疗蓬佩病的用途 | |
| JP2020505330A5 (enExample) | ||
| CN113166240A (zh) | 肌肉靶向复合物及其用于治疗弗里德赖希共济失调的用途 |